Skip to main content
NCBI home page
Gut logoLink to Gut
. 2000 Aug;47(2):159–161. doi: 10.1136/gut.47.2.159

The science, economics, and effectiveness of combination therapy for hepatitis C

G DUSHEIKO 1, E BARNES 1, G WEBSTER 1, S WHALLEY 1
PMCID: PMC1728019  PMID: 10896900

Full Text

The Full Text of this article is available as a PDF (78.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alter M. J., Kruszon-Moran D., Nainan O. V., McQuillan G. M., Gao F., Moyer L. A., Kaslow R. A., Margolis H. S. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999 Aug 19;341(8):556–562. doi: 10.1056/NEJM199908193410802. [DOI] [PubMed] [Google Scholar]
  2. Beard M. R., Abell G., Honda M., Carroll A., Gartland M., Clarke B., Suzuki K., Lanford R., Sangar D. V., Lemon S. M. An infectious molecular clone of a Japanese genotype 1b hepatitis C virus. Hepatology. 1999 Jul;30(1):316–324. doi: 10.1002/hep.510300137. [DOI] [PubMed] [Google Scholar]
  3. Cacciola I., Pollicino T., Squadrito G., Cerenzia G., Orlando M. E., Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999 Jul 1;341(1):22–26. doi: 10.1056/NEJM199907013410104. [DOI] [PubMed] [Google Scholar]
  4. Darby S. C., Ewart D. W., Giangrande P. L., Spooner R. J., Rizza C. R., Dusheiko G. M., Lee C. A., Ludlam C. A., Preston F. E. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet. 1997 Nov 15;350(9089):1425–1431. doi: 10.1016/s0140-6736(97)05413-5. [DOI] [PubMed] [Google Scholar]
  5. Davis G. L. Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Semin Liver Dis. 1999;19 (Suppl 1):49–55. [PubMed] [Google Scholar]
  6. Dienstag J. L. The natural history of chronic hepatitis C and what we should do about it. Gastroenterology. 1997 Feb;112(2):651–655. doi: 10.1053/gast.1997.v112.agast970651. [DOI] [PubMed] [Google Scholar]
  7. Dusheiko G., Main J., Thomas H., Reichard O., Lee C., Dhillon A., Rassam S., Fryden A., Reesink H., Bassendine M. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol. 1996 Nov;25(5):591–598. doi: 10.1016/s0168-8278(96)80225-x. [DOI] [PubMed] [Google Scholar]
  8. Dusheiko G., Simmonds P. Sequence variability of hepatitis C virus and its clinical relevance. J Viral Hepat. 1994;1(1):3–15. doi: 10.1111/j.1365-2893.1994.tb00057.x. [DOI] [PubMed] [Google Scholar]
  9. El-Serag H. B., Mason A. C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999 Mar 11;340(10):745–750. doi: 10.1056/NEJM199903113401001. [DOI] [PubMed] [Google Scholar]
  10. Hurtado K. Making sense of hepatitis C. Lancet. 1999 Feb 6;353(9151):500–500. doi: 10.1016/S0140-6736(05)75175-8. [DOI] [PubMed] [Google Scholar]
  11. Khakoo S., Glue P., Grellier L., Wells B., Bell A., Dash C., Murray-Lyon I., Lypnyj D., Flannery B., Walters K. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol. 1998 Dec;46(6):563–570. doi: 10.1046/j.1365-2125.1998.00836.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. McHutchison J. G., Gordon S. C., Schiff E. R., Shiffman M. L., Lee W. M., Rustgi V. K., Goodman Z. D., Ling M. H., Cort S., Albrecht J. K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998 Nov 19;339(21):1485–1492. doi: 10.1056/NEJM199811193392101. [DOI] [PubMed] [Google Scholar]
  13. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997 Mar 22;349(9055):825–832. doi: 10.1016/s0140-6736(96)07642-8. [DOI] [PubMed] [Google Scholar]
  14. Poynard T., Marcellin P., Lee S. S., Niederau C., Minuk G. S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet. 1998 Oct 31;352(9138):1426–1432. doi: 10.1016/s0140-6736(98)07124-4. [DOI] [PubMed] [Google Scholar]
  15. Rawlins M. In pursuit of quality: the National Institute for Clinical Excellence. Lancet. 1999 Mar 27;353(9158):1079–1082. doi: 10.1016/S0140-6736(99)02381-8. [DOI] [PubMed] [Google Scholar]
  16. Simmonds P., Mellor J., Craxi A., Sanchez-Tapias J. M., Alberti A., Prieto J., Colombo M., Rumi M. G., Lo Iacano O., Ampurdanes-Mingall S. Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients. J Hepatol. 1996 May;24(5):517–524. doi: 10.1016/s0168-8278(96)80135-8. [DOI] [PubMed] [Google Scholar]
  17. Zitzmann N., Mehta A. S., Carrouée S., Butters T. D., Platt F. M., McCauley J., Blumberg B. S., Dwek R. A., Block T. M. Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):11878–11882. doi: 10.1073/pnas.96.21.11878. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES